Africa Molecular Point of Care Testing (Using NAAT) Market - Industry Trends and Forecast to 2028
- Published Date: 2022-11-21
- Report ID: 144470
- Pages: 200
-
Format:
Short Description
Africa Molecular Point of Care Testing (Using NAAT), By Product (Instruments And Consumables And Reagents), Indication (Respiratory Infections Testing, Sexually Transmitted Infection (STI) Testing, Gastrointestinal Tract Infections Testing And Others), End User ( Laboratories, Hospitals, Clinics, Home Care, Ambulatory Centers, Assisted Living Facilities And Others), Mode Of Testing ( Prescription-Based Testing And OTC-Based Testing), Distribution Channel (Direct Sales, Third Party Distributors, Online Sales), Country (Kenya, Nigeria And Rest Of Africa), Industry Trends and Forecast To 2028
Market Definition
Point of Care Testing (POCT) is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering into clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically in the range of 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30x30cm. These instruments are essentially used in the molecular detection of various disorders such as HIV, HPV, and respiratory disease through nucleic acid amplification techniques (NAAT) technology. NAAT allows the identification of pathogenic organisms by detecting their DNA or RNA.
In the global pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propel the growth of the market.
Molecular point-of-care testing's significant advantages include the rapid diagnosis process, treatment choice, monitoring, and prognosis. This will also help in operational decision-making and proper resource utilization.
Market Segmentation
Africa molecular point of care testing (using NAAT) market is categorized into five notable segments, which are based on product, indication, end user, mode of testing, and distribution channel.
On the basis of product, the Africa molecular point of care testing (using NAAT) market is segmented into instruments, consumables, and reagents
On the basis of indication, the Africa molecular point of care testing (using NAAT) market is segmented into sexually transmitted infection (STI) testing, respiratory infection testing, gastrointestinal tract infection testing, and others
On the basis of end user, the Africa molecular point of care testing (using NAAT) market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, and others
On the basis of mode of testing, the Africa molecular point of care testing (using NAAT) market is segmented into prescription-based testing and OTC testing
On the basis of distribution channel, the Africa molecular point of care testing (using NAAT) market is segmented into direct tender, third party distributor, and online sales
Market Players
Some of the key market players for Africa molecular point of care testing (using NAAT) market are listed below:
Hologic, Inc.
F. Hoffmann-La Roche Ltd
ABBOTT
Seegene Inc.
bioMrieux SA
QIAGEN
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Quidel Corporation
GenMark Diagnostics, Inc.
SD Biosensor, INC.
Meridian Bioscience
TABLE OF CONTENTS
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.3 OVERVIEW OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 42
1.4 LIMITATIONS 44
1.5 MARKETS COVERED 44
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 CURRENCY AND PRICING 48
2.5 DBMR TRIPOD DATA VALIDATION MODEL 49
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.7 MULTIVARIATE MODELLING 53
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 56
2.11 MARKET END USER COVERAGE GRID 57
2.12 SECONDARY SOURCES 58
2.13 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 62
4.1 PORTERS FIVE FORCES 63
4.2 PESTEL ANALYSIS 64
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES 65
4.3.1 CEPHEID 65
4.3.2 THERMO FISHER SCIENTIFIC INC. 66
4.3.3 HOLOGIC, INC. 67
4.3.4 BD 68
4.3.5 F. HOFFMANN-LA ROCHE LTD 69
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY 70
4.5 PRICE PER POCT INSTRUMENT 71
4.5.1 NORTH AMERICA 71
4.5.2 EUROPE 73
4.5.3 SOUTH ASIA 74
4.5.4 SOUTH EAST ASIA 76
4.5.5 MIDDLE EAST 79
4.5.6 AFRICA 81
4.6 PRICE PER TEST 83
4.6.1 NORTH AMERICA 83
4.6.2 EUROPE 91
4.6.3 SOUTH ASIA 99
4.6.4 SOUTH EAST ASIA 107
4.6.5 MIDDLE EAST 119
4.6.6 AFRICA 131
4.7 MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS 139
4.8 MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) 143
4.9 MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS 147
4.10 MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS 150
4.11 DISTRIBUTORS 153
4.11.1 NORTH AMERICA 153
4.11.2 EUROPE 154
4.11.3 SOUTH ASIA 156
4.11.4 SOUTH EAST ASIA 157
4.11.5 MIDDLE EAST 159
4.11.6 AFRICA 160
5 REGULATORY FRAMEWORK 161
6 MARKET OVERVIEW 164
6.1 DRIVERS 166
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 166
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE 166
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 167
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE 167
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING 168
6.2 RESTRAINTS 169
6.2.1 PRODUCT RECALLS 169
6.2.2 HIGH COSTS OF PRODUCTS 169
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS 170
6.3 OPPORTUNITIES 170
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 170
6.3.2 RISING HEALTHCARE EXPENDITURE 171
6.3.3 PANDEMIC OUTBREAK OF COVID-19 172
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 172
6.4 CHALLENGES 173
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES 173
6.4.2 LACK OF ACCESSIBILITY 173
7 IMPACT OF COVID-19 ON THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 175
7.1 IMPACT ON PRICE 175
7.2 IMPACT ON DEMAND 175
7.3 IMPACT ON SUPPLY CHAIN 176
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19 176
7.5 CONCLUSION: 177
8 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT 178
8.1 OVERVIEW 179
8.2 CONSUMABLES & REAGENTS 182
8.3 INSTRUMENTS 182
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE) 183
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM) 183
9 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION 184
9.1 OVERVIEW 185
9.2 RESPIRATORY INFECTIONS TESTING 188
9.2.1 COVID-19 189
9.2.2 FLU B 189
9.2.3 FLU A 189
9.2.4 RSV 189
9.2.5 TUBERCULOSIS 189
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA) 189
9.2.7 OTHERS 190
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING 190
9.3.1 TV 191
9.3.2 CT 191
9.3.3 NG 191
9.3.4 HPV 191
9.3.5 HSV 191
9.3.6 MG 191
9.3.7 UU 192
9.3.8 MH 192
9.3.9 OTHERS 192
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING 192
9.4.1 GROUP B STREPTOCOCCUS 193
9.4.2 SHIGA TOXIN 193
9.4.3 H. PYLORI 193
9.5 OTHERS 194
10 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER 195
10.1 OVERVIEW 196
10.2 LABORATORIES 199
10.3 HOSPITAL 199
10.4 CLINICS 200
10.5 AMBULATORY CENTER 201
10.6 HOMECARE 201
10.7 ASSISTED LIVING FACILITIES 202
10.8 OTHERS 203
11 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING 204
11.1 OVERVIEW 205
11.2 PRESCRIPTION-BASED TESTING 208
11.3 OTC TESTING 209
12 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL 210
12.1 OVERVIEW 211
12.2 DIRECT SALES 214
12.3 THIRD PARTY DISTRIBUTOR 214
12.4 ONLINE SALES 215
13 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 216
13.1 AFRICA 217
13.1.1 SOUTH AFRICA 225
13.1.2 KENYA 229
13.1.3 NIGERIA 233
13.1.4 REST OF AFRICA 237
14 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE 238
14.1 COMPANY SHARE ANALYSIS: AFRICA 238
15 SWOT ANALYSIS 239
16 COMPANY PROFILE 240
16.1 DANAHER 240
16.1.1 COMPANY SNAPSHOT 240
16.1.2 REVENUE ANALYSIS 240
16.1.3 COMPANY SHARE ANALYSIS 241
16.1.4 PRODUCT PORTFOLIO 241
16.1.5 RECENT DEVELOPMENTS 242
16.2 THERMO FISHER SCIENTIFIC INC. 243
16.2.1 COMPANY SNAPSHOT 243
16.2.2 REVENUE ANALYSIS 243
16.2.3 COMPANY SHARE ANALYSIS 244
16.2.4 PRODUCT PORTFOLIO 244
16.2.5 RECENT DEVELOPMENTS 244
16.3 HOLOGIC, INC. 245
16.3.1 COMPANY SNAPSHOT 245
16.3.2 REVENUE ANALYSIS 245
16.3.3 COMPANY SHARE ANALYSIS 246
16.3.4 PRODUCT PORTFOLIO 246
16.3.5 RECENT DEVELOPMENTS 246
16.4 BD 247
16.4.1 COMPANY SNAPSHOT 247
16.4.2 REVENUE ANALYSIS 247
16.4.3 COMPANY SHARE ANALYSIS 248
16.4.4 PRODUCT PORTFOLIO 248
16.4.5 RECENT DEVELOPMENTS 248
16.5 F.HOFFMANN-LA-ROCHE LTD. 249
16.5.1 COMPANY SNAPSHOT 249
16.5.2 REVENUE ANALYSIS 249
16.5.3 COMPANY SHARE ANALYSIS 250
16.5.4 PRODUCT PORTFOLIO 250
16.5.5 RECENT DEVELOPMENTS 251
16.6 ABBOTT 252
16.6.1 COMPANY SNAPSHOT 252
16.6.2 REVENUE ANALYSIS 252
16.6.3 PRODUCT PORTFOLIO 253
16.6.4 RECENT DEVELOPMENTS 253
16.7 BINX HEALTH, INC. 254
16.7.1 COMPANY SNAPSHOT 254
16.7.2 PRODUCT PORTFOLIO 254
16.7.3 RECENT DEVELOPMENT 254
16.8 BIOMERIEUX SA 255
16.8.1 COMPANY SNAPSHOT 255
16.8.2 REVENUE ANALYSIS 255
16.8.3 PRODUCT PORTFOLIO 256
16.8.4 RECENT DEVELOPMENT 256
16.9 BIO-RAD LABORATORIES, INC. 257
16.9.1 COMPANY SNAPSHOT 257
16.9.2 REVENUE ANALYSIS 257
16.9.3 PRODUCT PORTFOLIO 258
16.9.4 RECENT DEVELOPMENTS 258
16.10 CO-DIAGNOSTICS, INC. 260
16.10.1 COMPANY SNAPSHOT 260
16.10.2 REVENUE ANALYSIS 260
16.10.3 PRODUCT PORTFOLIO 261
16.10.4 RECENT DEVELOPMENTS 261
16.11 GENMARK DIAGNOSTICS, INC 262
16.11.1 COMPANY SNAPSHOT 262
16.11.2 REVENUE ANALYSIS 262
16.11.3 PRODUCT PORTFOLIO 263
16.11.4 RECENT DEVELOPMENT 263
16.12 GRIFOLS, S.A. 264
16.12.1 COMPANY SNAPSHOT 264
16.12.2 REVENUE ANALYSIS 264
16.12.3 PRODUCT PORTFOLIO 265
16.12.4 RECENT DEVELOPMENT 265
16.13 LUCIRA HEALTH INC. 266
16.13.1 COMPANY SNAPSHOT 266
16.13.2 PRODUCT PORTFOLIO 266
16.13.3 RECENT DEVELOPMENTS 266
16.14 MERIDIAN BIOSCIENCE 267
16.14.1 COMPANY SNAPSHOT 267
16.14.2 REVENUE ANALYSIS 267
16.14.3 PRODUCT PORTFOLIO 268
16.14.4 RECENT DEVELOPMENTS 268
16.15 OXFORD NANOPORE TECHNOLOGIES 269
16.15.1 COMPANY SNAPSHOT 269
16.15.2 PRODUCT PORTFOLIO 269
16.15.3 RECENT DEVELOPMENT 269
16.16 PERKIN ELMER INC. 270
16.16.1 COMPANY SNAPSHOT 270
16.16.2 REVENUE ANALYSIS 270
16.16.3 PRODUCT PORTFOLIO 271
16.16.4 RECENT DEVELOPMENT 271
16.17 QIAGEN 272
16.17.1 COMPANY SNAPSHOT 272
16.17.2 REVENUE ANALYSIS 272
16.17.3 PRODUCT PORTFOLIO 273
16.17.4 RECENT DEVELOPMENTS 273
16.18 QUANTUMDX GROUP LTD. 275
16.18.1 COMPANY SNAPSHOT 275
16.18.2 PRODUCT PORTFOLIO 275
16.18.3 RECENT DEVELOPMENTS 275
16.19 QUIDEL CORPORATION 277
16.19.1 COMPANY SNAPSHOT 277
16.19.2 REVENUE ANALYSIS 277
16.19.3 PRODUCT PORTFOLIO 278
16.19.4 RECENT DEVELOPMENT 278
16.20 RANDOX LABORATORIES LTD. 279
16.20.1 COMPANY SNAPSHOT 279
16.20.2 PRODUCT PORTFOLIO 279
16.20.3 RECENT DEVELOPMENTS 279
16.21 SD BIOSENSOR, INC. 281
16.21.1 COMPANY SNAPSHOT 281
16.21.2 PRODUCT PORTFOLIO 281
16.21.3 RECENT DEVELOPMENT 281
16.22 SEEGENE INC, 282
16.22.1 COMPANY SNAPSHOT 282
16.22.2 REVENUE ANALYSIS 282
16.22.3 PRODUCT PORTFOLIO 283
16.22.4 RECENT DEVELOPMENT 283
16.23 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL) 284
16.23.1 COMPANY SNAPSHOT 284
16.23.2 PRODUCT PORTFOLIO 284
16.23.3 RECENT DEVELOPMENT 284
16.24 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION 286
16.24.1 COMPANY SNAPSHOT 286
16.24.2 REVENUE ANALYSIS 286
16.24.3 PRODUCT PORTFOLIO 287
16.24.4 RECENT DEVELOPMENT 287
16.25 WONDFO 288
16.25.1 COMPANY SNAPSHOT 288
16.25.2 PRODUCT PORTFOLIO 288
16.25.3 RECENT DEVELOPMENT 288
17 QUESTIONNAIRE 289
18 RELATED REPORTS 292
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
